Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma.
暂无分享,去创建一个
L. Nardo | R. Pierce | A. Daud | M. Rosenblum | M. Krummel | A. Algazi | I. Lobach | Jimmy Hwang | M. Pampaloni | Adi Nosrati | M. Pauli | I. Gratz | K. Loo | Michael D. Alvarado | P. M. Sandoval | K. Tsai | Keyon Taravati | R. Sanchez-Rodriguez
[1] Dana Pe'er,et al. PD-1 Blockade Expands Intratumoral Memory T Cells , 2016, Cancer Immunology Research.
[2] G. Freeman,et al. Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma , 2015, Cancer Immunology Research.
[3] J. Madore,et al. PD‐L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti‐PD‐1/PD‐L1 clinical trials , 2015, Pigment cell & melanoma research.
[4] E. Wherry,et al. Overcoming T cell exhaustion in infection and cancer. , 2015, Trends in immunology.
[5] H. An,et al. Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis. , 2015, Journal of thoracic disease.
[6] F. Cappuzzo,et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. , 2015, The Lancet. Oncology.
[7] Razelle Kurzrock,et al. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy , 2015, Molecular Cancer Therapeutics.
[8] H. Kohrt,et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.
[9] M. Atkins,et al. Prognostic and predictive markers for the new immunotherapies. , 2014, Oncology.
[10] R. Emerson,et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.
[11] D. Douek,et al. PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors. , 2014, The Journal of clinical investigation.
[12] S. Arron,et al. Memory regulatory T cells reside in human skin. , 2014, The Journal of clinical investigation.
[13] Antoni Ribas,et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.
[14] E John Wherry,et al. T cell exhaustion , 2011 .
[15] Israel Lowy,et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] S. Rosenberg,et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. , 2009, Blood.
[17] J. Altman,et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. , 2008, Immunity.
[18] G. Freeman,et al. Reinvigorating exhausted HIV-specific T cells via PD-1–PD-1 ligand blockade , 2006, The Journal of experimental medicine.
[19] L. Austin,et al. CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry. , 2000, Journal of autoimmunity.
[20] G. Vanham,et al. Expression of activation antigens, HLA‐DR and CD38, on CD8 lymphocytes during HIV‐1 infection , 1992, AIDS.